Back to search

Article

Comparative Efficacy and Safety of GLP-1 Receptor Agonists in Neurological and Nephrological Outcomes of Type 2 Diabetes: A Systematic Review and Network Meta-Analysis

2025-09-02

Abstract excerpt

<h4>Introduction</h4> Type 2 diabetes (T2D) is associated with significant neurological and nephrological complications, leading to high morbidity and mortality. GLP-1 receptor agonists (GLP-1 RAs), such as liraglutide, semaglutide, and tirzepatide, have been shown to effectively control glycemia, with additional neuroprotective and nephroprotective effects. This systematic review and network meta-analysis (NMA)...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
3b994853-0c9b-5880-a3c1-94c258890750
DOI
10.1101/2025.09.01.25334855
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Comparative Efficacy and Safety of GLP-1 Receptor Agonists in Neurological and Nephrological Outcomes of Type 2 Diabetes: A Systematic Review and Network Meta-AnalysisDOI 10.1101/2025.09.01.25334855
Cardiorenal outcomes of tirzepatide versus semaglutide in adults with type 2 diabetes and chronic kidney disease: a target trial emulation in the TriNetX Global Collaborative NetworkSemantic proximity
Efficacy and Safety of SGLT2 Inhibitors in the Treatment of Type 2 Diabetes: An Umbrella ReviewSemantic proximity
Neuro-Adverse Events Associated with GLP-1 Receptor Agonists: A Study Based on the FAERS Database and External Validation Using NHANES DatabaseSemantic proximity
GLP1R gene expression is associated with metabolic and mental health effects in a phenome-wide drug repurposing and safety analysisSemantic proximity
Design and discovery of a highly potent ultralong-acting GLP-1 and glucagon co-agonist for attenuating renal fibrosis by modulating mitochondrial functionSemantic proximity
Neurosensory Risk After Semaglutide or Tirzepatide Is Lower Than Matched Antidiabetic and Bariatric Surgery Cohorts and Tracks Glycemic BurdenSemantic proximity
GLP Medications and Severe Post-COVID-19 Outcomes Among Individuals with Type 2 Diabetes MellitusSemantic proximity
Phenome-wide analysis of downstream health outcomes following second-line antidiabetic agent prescriptions in All of Us.Semantic proximity
Chronic kidney disease in type 1 diabetes: translation of novel type 2 diabetes therapeutics to individuals with type 1 diabetesSemantic proximity
Heterogeneity of Treatment Effects of Glucose-lowering Drug Classes for Type 2 Diabetes: LEGEND-T2DM Network Real-World EvidenceSemantic proximity
Renal outcomes of combination therapy with sodium-glucose cotransporter 2 inhibitors plus renin-angiotensin system blockers in patients with type 2 diabetes mellitus: A population-based cohort studySemantic proximity
Chronic Kidney Disease in the Elderly Patient with DiabetesSemantic proximity
Select a neighboring publication to make it the new centre.